| 31.04 0.26 (0.84%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 38.61 | 1-year : | 41.88 |
| Resists | First : | 33.05 | Second : | 35.86 |
| Pivot price | 31.94  |
|||
| Supports | First : | 28.53 | Second : | 23.73 |
| MAs | MA(5) : | 31.98  |
MA(20) : | 31.82 |
| MA(100) : | 36.81 |
MA(250) : | 46.62 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 34 |
D(3) : | 51.9 |
| RSI | RSI(14): 43 |
|||
| 52-week | High : | 72.94 | Low : | 28.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BRKR ] has closed above bottom band by 27.2%. Bollinger Bands are 42.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 31.56 - 31.73 | 31.73 - 31.89 |
| Low: | 30.28 - 30.51 | 30.51 - 30.72 |
| Close: | 30.71 - 31.04 | 31.04 - 31.35 |
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Thu, 25 Sep 2025
Q2 Earnings Highs And Lows: Bruker (NASDAQ:BRKR) Vs The Rest Of The Research Tools & Consumables Stocks - Yahoo Finance
Tue, 23 Sep 2025
Could Bruker (BRKR)'s Innovation Showcase at Lyon Signal a Shift in Its Competitive Position? - simplywall.st
Sun, 21 Sep 2025
Bruker Corporation (NASDAQ:BRKR) Short Interest Up 25.6% in August - MarketBeat
Thu, 18 Sep 2025
Advisors Capital Management LLC Acquires 8,745 Shares of Bruker Corporation $BRKR - MarketBeat
Thu, 18 Sep 2025
Amundi Purchases 33,522 Shares of Bruker Corporation $BRKR - MarketBeat
Tue, 16 Sep 2025
Bruker Corporation (BRKR): A Bull Case Theory - Yahoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 152 (M) |
| Shares Float | 103 (M) |
| Held by Insiders | 31.9 (%) |
| Held by Institutions | 84.5 (%) |
| Shares Short | 8,350 (K) |
| Shares Short P.Month | 9,330 (K) |
| EPS | 0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.89 |
| Profit Margin | 2.3 % |
| Operating Margin | 3.6 % |
| Return on Assets (ttm) | 3.5 % |
| Return on Equity (ttm) | 4 % |
| Qtrly Rev. Growth | -0.5 % |
| Gross Profit (p.s.) | 11.13 |
| Sales Per Share | 22.67 |
| EBITDA (p.s.) | 3.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 166 (M) |
| Levered Free Cash Flow | 223 (M) |
| PE Ratio | 59.69 |
| PEG Ratio | 0 |
| Price to Book value | 2.61 |
| Price to Sales | 1.36 |
| Price to Cash Flow | 28.38 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|